Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Noble Energy Announces First Quarter Results
12:00am, Friday, 08'th May 2020
Noble Energy, Inc. (NASDAQ: NBL) (“Noble Energy” or the “Company”) today provided first quarter financial and operating results. First quarter highlig
Atara Biotherapeutics Inc (ATRA) Q1 2020 Earnings Call Transcript
06:00pm, Thursday, 07'th May 2020
Ladies and gentlemen, thank you for standing by, and welcome to the Atara Biotherapeutics First Quarter 2020 Financial Results Conference Call. Thank you, Eric, and thanks to all of you for joining u
Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT
11:29am, Thursday, 07'th May 2020
Q1 2020 Atara Biotherapeutics Inc Earnings Call
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call Transcript
03:23am, Thursday, 07'th May 2020
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2020 Results Conference Call May 06, 2020 04:30 PM ET Company Participants Eric Hyllengren - Vice President of Inve
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
08:01pm, Wednesday, 06'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Reviewing Neon Therapeutics (NASDAQ:NTGN) & Atara Biotherapeutics (NASDAQ:ATRA)
09:20am, Saturday, 02'nd May 2020
Neon Therapeutics (NASDAQ:NTGN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the streng
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX)
03:50pm, Friday, 01'st May 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX) with
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Dynavax (NASDAQ: DVAX)
03:50pm, Friday, 01'st May 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (
BMRN
–
Research Report
) and Dynavax (
DVAX
–
Research Report
) with bull
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
10:08am, Friday, 01'st May 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Kiadis Pharma (KIADF) yesterday and set a price target of EUR4.00. The company's shares
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
10:08am, Friday, 01'st May 2020
Canaccord Genuity analyst
John Newman
maintained a
Buy
rating on Kiadis Pharma (
KIADF
–
Research Report
) yesterday and set a price target of
EUR4.00
. The company’s shares closed last Monday at
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO), with a price target of $72.00. The
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday,
John Newman
from Canaccord Genuity maintained a
Buy
rating on Agios Pharma (
AGIO
–
Research Report
), with a price target of
$72.00
. The company’s shares closed l
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
09:44pm, Thursday, 30'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN), with a price target of $215.00. The company's
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
09:43pm, Thursday, 30'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN – Research Report),
